Skip to main content
Premium Trial:

Request an Annual Quote

Will This Help or Hurt My Odds?

DrugMonkey asks: "Should you mention your grant score in your tenure-track job application?" In considering recent topical posts by Dr. O and mumbercycle, DrugMonkey says that in the event that early-career applicants have applied for a K grant, they probably should. "Although in this day and age you will be competing with many people who have also submitted grant applications, there will be those who have not. This puts you ahead of the game," he says, adding that scored K grants put young investigators in "the 'competitive for funding' category." However, if applicants' grant had been triaged, DrugMonkey says it's probably best not to "lead with this information." He says that if including unfunded grant scores in an application seems unnatural, they might opt to put them in their CV. He suggests alerting search committees to the "great science you want to accomplish by pointing out that 'some of these experiments have been proposed in a K99/R00 application that received a priority score of XX. While not competitive for funding at this time, this shows the considerable enthusiasm of NIH reviewers for these studies.'"

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.